E-LIB Suche - Ergebnisse für: Siegel, David S.

1

Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (..:

Patel, Krina K. ; Rodríguez-Otero, Paula ; Nooka, Ajay K....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S322 , 2024

Link: https://doi.org/10.1016/..

2

MM-371 Pomalidomide, Daratumumab, and Dexamethasone After L..:

Bahlis, Nizar J. ; Samaras, Christy ; Reece, Donna...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S494-S495 , 2023

Link: https://doi.org/10.1016/..

3

POSTER: MM-371 Pomalidomide, Daratumumab, and Dexamethasone..:

Bahlis, Nizar J. ; Samaras, Christy ; Reece, Donna...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S225 , 2023

Link: https://doi.org/10.1016/..

4

Idecabtagene vicleucel for relapsed and refractory multiple..:

Lin, Yi ; Raje, Noopur S. ; Berdeja, Jesús G....
Nature Medicine. 29 (2023) 9 - p. 2286-2294 , 2023

Link: https://doi.org/10.1038/..

5

Sustained Hematopoietic Engraftment Potential after Prolong..:

Makhani, Sarah S. ; Oza, Samir P. ; Reich-Slotky, Ronit...
Transplantation and Cellular Therapy. 28 (2022) 6 - p. 306.e1-306.e7 , 2022

Link: https://doi.org/10.1016/..

6

Natural killer cells activity against multiple myeloma cell..:

Uhl, Christopher ; Nyirenda, Themba ; Siegel, David S...
Heliyon. 8 (2022) 3 - p. e09167 , 2022

Link: https://doi.org/10.1016/..

7

Pomalidomide, dexamethasone, and daratumumab immediately af..:

Bahlis, Nizar J. ; Siegel, David S. ; Schiller, Gary J....
Leukemia & Lymphoma. 63 (2022) 6 - p. 1407-1417 , 2022

Link: https://doi.org/10.1080/..

8

Preferences and Priorities for Relapsed Multiple Myeloma Tr..:

Auclair, Daniel ; Mansfield, Carol ; Fiala, Mark A...
Patient Preference and Adherence. 16 (2022) - p. 573-585 , 2022

Link: https://doi.org/10.2147/..

9

P-279: Efficacy, safety, and pharmacokinetics of iberdomide..:

van de Donk, Niels W.C.J. ; Raab, Marc S. ; Besemer, Britta...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S191-S192 , 2022

Link: https://doi.org/10.1016/..

10

P-232: Adverse event patterns and management with pomalidom..:

Bahlis, Nizar ; Schiller, Gary ; Samaras, Christy J....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S162-S163 , 2022

Link: https://doi.org/10.1016/..

11

I-OPen: inferior outcomes of penta-refractory compared to p..:

Gill, Sarvarinder K. ; Unawane, Rashmi ; Wang, Shuqi...
Blood Cancer Journal. 12 (2022) 9 - p. , 2022

Link: https://doi.org/10.1038/..

12

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-d..:

Jr, Larry D. Anderson, ; Shah, Nina ; Jagannath, Sundar...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S17-S18 , 2021

Link: https://doi.org/10.1016/..

13

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Re..:

Raje, Noopur S. ; Siegel, David S. ; Jagannath, Sundar...
Transplantation and Cellular Therapy. 27 (2021) 3 - p. S66-S67 , 2021

Link: https://doi.org/10.1016/..

14

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2..:

Berdeja, Jesus G. ; Raje, Noopur S. ; Siegel, David S....
Transplantation and Cellular Therapy. 27 (2021) 3 - p. S397-S398 , 2021

Link: https://doi.org/10.1016/..

15

KarMMa-RW: comparison of idecabtagene vicleucel with real-w..:

Jagannath, Sundar ; Lin, Yi ; Goldschmidt, Hartmut...
Blood Cancer Journal. 11 (2021) 6 - p. , 2021

Link: https://doi.org/10.1038/..